Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $7 to $19, according to analysts polled by Capital IQ. (MT...
Axcella (AXLA) said Thursday it has completed the enrollment of 40 patients into a phase 2a trial of AXA1125 as a potential treatment for long COVID-19, a...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
| Address | 840 Memorial Drive Cambridge, Massachusetts 02139 |
| Phone | +1.857.320.2200 |
| Number of Employees | 49 |
| Recent SEC Filing | 06/03/2022 4 |
| President, Chief Executive Officer & Director | William R. Hinshaw |
| Chief Financial Officer & Senior Vice President | Robert W. Crane |
| Chief Scientific Officer, Senior VP-R&D | Tony Tramontin |
| Chief Medical Officer & Senior Vice President | Margaret Koziel |
| Price Open | $1.90 |
| Previous Close | $1.88 |
| 52 Week Range | $1.35 - 4.81 |
| Market Capitalization | $100.9 M |
| Shares Outstanding | 52.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.75 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -202.08% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
